May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Real-World Cost of Treating Neovascular Age-Related Macular Degeneration With Bevacizumab
Author Affiliations & Notes
  • L. M. Smithen
    Ophthalmology, Tufts-New England Medical Center, Boston, Massachusetts
  • J. S. Duker
    Ophthalmology, Tufts-New England Medical Center, Boston, Massachusetts
  • E. Reichel
    Ophthalmology, Tufts-New England Medical Center, Boston, Massachusetts
  • C. R. Baumal
    Ophthalmology, Tufts-New England Medical Center, Boston, Massachusetts
  • A. H. Rogers
    Ophthalmology, Tufts-New England Medical Center, Boston, Massachusetts
  • Footnotes
    Commercial Relationships L.M. Smithen, None; J.S. Duker, None; E. Reichel, None; C.R. Baumal, None; A.H. Rogers, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2100. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. M. Smithen, J. S. Duker, E. Reichel, C. R. Baumal, A. H. Rogers; Real-World Cost of Treating Neovascular Age-Related Macular Degeneration With Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2100. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To calculate the actual cost associated with treating neovascular Age-Related Macular Degeneration (ARMD) with bevacizumab (Avastin) and to determine the interval between injections.

Methods:: Consecutive patients with neovascular ARMD treated with intravitreal bevacizumab injections at the home institution were identified. Patient charts were reviewed and the number and date of all injections was documented. Descriptive information was gathered. Average cost of bevacizumab was obtained and average real-world cost calculations were determined. Extrapolations were made to the overall neovascular ARMD population and estimates of overall treatment cost were established. The average interval between bevacizumab injections was also calculated.

Results:: Consecutive patients with neovascular ARMD treated with intravitreal bevacizumab injections at the home institution were identified. Patient charts were reviewed and the number and date of all injections was documented. Descriptive information was gathered. Average cost of bevacizumab was obtained and average real-world cost calculations were determined. Extrapolations were made to the overall neovascular ARMD population and estimates of overall treatment cost were established. The average interval between bevacizumab injections was also calculated.

Conclusions:: The real-world cost of treating neovascular ARMD for one year exceeds $190 million.

Keywords: age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×